CanSino Biologics (SHA:688185, HKG:6185) has begun its phase 2/3 clinical trial for its combined vaccine for absorbed diphtheria, tetanus, and acellular pertussis, and enrolled its first patient in its phase 2 trial.
The Tdcp vaccine is indicated for adolescents and adults aged six years old and above, according to a Friday filing with the Hong Kong exchange.
CanSino's vaccine will also help address a vaccination gap for booster shots for Tdcp, according to the filing.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。